Akèy › Limfòm Burkitt › Kalifòni › San Bernardino

Etid klinik pou Limfòm Burkitt nan San Bernardino, CA

4 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan ak bò kote San Bernardino (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Ap rekriteFaz 2

Loma Linda University Medical Center, Loma Linda · 4 mi lwen

366 Days – 46 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Ap rekriteFaz 2

Loma Linda University Medical Center, Loma Linda · 4 mi lwen

365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ap rekriteFaz 2

Loma Linda University Medical Center, Loma Linda · 4 mi lwen

Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Ap rekriteFaz 3

Loma Linda University Medical Center, Loma Linda · 4 mi lwen

365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

Etid Limfòm Burkitt nan lòt vil

Lòt etid nan San Bernardino

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.